Thomas Meier
Founder at SANTHERA PHARMACEUTICALS HOLDING AG
Net worth: 152 196 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Emanuele | M | 69 |
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
| Simon Jules Nebel | M | 58 |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | 8 years |
| James Sapirstein | M | 63 | - | |
| Santosh Vetticaden | M | 65 |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
| Dario Eklund | M | 56 | 5 years | |
| Eliahu Kaplan | M | - |
Novaremed AG
 Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | 16 years |
| Timothy Ramdeen | M | 32 | 1 years | |
| Philipp Gutzwiller | M | 56 | 7 years | |
| William Pedranti | M | - |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | 1 years |
| Liat Hochman | F | - |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | 13 years |
| Oliver Strub | M | 61 | 18 years | |
| Ajit Singh | M | 60 | - | |
| Ulf Grawunder | M | 59 |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland.
University of Basel
| 6 years |
| Marc Schrader | M | - | 2 years | |
| Ralph Schiess | M | 46 | 1 years | |
| Andreas Missy | M | - | 4 years | |
| Bradley Meyer | M | - | 1 years | |
| Neville Kodkani | M | - | 9 years | |
| Dorota Skowronska-Krawczyk | M | - |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
| S K Tan | M | - |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | - |
| Stephanie Brown | F | - | 3 years | |
| Daniel L. Chao | M | - |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
| Shabir Hasham | M | - | 9 years | |
| Simon Tarsh | M | 63 | 2 years | |
| Sarah Holmes-Klotz | F | - | 2 years | |
| Eva Kalias | F | - | - | |
| Eric Carter | M | 72 |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | 2 years |
| Otto Schwarz | M | 68 | 1 years | |
| Alan Tyndall | M | 76 |
University of Basel
| 33 years |
| Thomas Meier | M | - |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
| Joseph Feinstein | M | - |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | - |
| Limor Kohen | F | 60 |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | - |
| Günther Metz | M | 66 | 20 years | |
| Andrew P. Smith | M | 61 | 4 years | |
| Isaac Kobrin | M | 75 |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | 7 years |
| Henner Schierenbeck | M | 78 |
University of Basel
| 34 years |
| Mark Altmeyer | M | 63 |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | 3 years |
| Bruce Harmon | M | 66 | 1 years | |
| Andrew Oakley | M | 62 |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | - |
| Elaine Heron | M | 76 |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
| Arthur Becker | M | 74 |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
| Geert Jan van Daal | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Barbara Anna Heller | F | 56 | 7 years | |
| Martin Gertsch | M | 59 | 15 years | |
| Elmar Schnee | M | 65 | 5 years | |
| Rico Buchli | M | - |
University of Basel
| 5 years |
| Patrick Volkert Vink | M | 60 | 6 years | |
| Christoph Rentsch | M | 65 | 4 years | |
| Beat Oberlin | M | 69 |
University of Basel
| 13 years |
| Subhasis Roy | M | 55 |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | 3 years |
| Rudolf Hausmann | M | - | - | |
| Oliver M. Bartholet | M | 58 |
University of Basel
| 7 years |
| Annelies Häcki Buhofer | M | 70 |
University of Basel
| 26 years |
| Jan Goepfert | M | 65 |
University of Basel
| 1 years |
| Daniel Petitjean | M | 54 |
University of Basel
| 6 years |
| Kristina Nygren | - | - | 4 years | |
| Max P. Sommer | M | 92 |
University of Basel
| 3 years |
| Andreas Wallnöfer | M | 63 |
University of Basel
| 2 years |
| Jürgen Eckhardt | M | 57 |
University of Basel
| 3 years |
| Todd Bazemore | M | 53 | 1 years | |
| Nicholas Coppard | M | 65 | 9 years | |
| Andreas C. Albrecht | M | 55 |
University of Basel
| 3 years |
| Giovanni Stropoli | M | 64 | - | |
| Kristina Sjöblom Nygren | M | 63 | 3 years | |
| Benyamin Sidon | M | 65 |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | - |
| Kimi Iguchi | F | 61 | 3 years | |
| Markus Nauck | M | 59 |
University of Basel
| 3 years |
| Sven Cattelan | M | 62 |
University of Basel
| 3 years |
| Georg Nebgen | M | 62 | - | |
| Bernd Seizinger | M | 67 | 7 years | |
| Michael Lytton | M | 67 | 7 years | |
| Hans-Peter Hasler | M | 68 | 5 years | |
| Mark C. Clement | M | - | 6 years | |
| Klaus Schollmeier | M | 67 | 9 years | |
| Stefan Mario Meister | M | 58 |
University of Basel
| 4 years |
| Beatrice Weder di Mauro | M | 57 |
University of Basel
| 3 years |
| Jürg Ambühl | M | 75 | - | |
| Yannick Hausmann | M | 57 |
University of Basel
| 3 years |
| Helmut H. Kessmann | M | 64 | 7 years | |
| Peter Wolf | M | - | - | |
| Rudolf Gygax | M | - | 5 years | |
| Raphael R. Hausmann | M | - |
University of Basel
| 1 years |
| Dirk Haasner | M | 59 |
University of Basel
| 4 years |
| Mátyás Végh | M | - |
University of Basel
| 4 years |
| Timothy James Rink | M | 78 | 9 years | |
| Magín Guardiola | M | 59 |
University of Basel
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 71 | 82.56% |
| United States | 15 | 17.44% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thomas Meier
- Personal Network